ARKG's recent activity highlights a strategic shift towards medical artificial intelligence, underscored by a significant purchase of Tempus AI (TEMP) shares. This move, coupled with a reduction in
Meta Platforms holdings, signals a clear preference for healthcare innovation over established tech giants. The ETF also continues to build its position in CRISPR Therapeutics (CRSP), adding substantial shares despite recent performance, supported by a favorable analyst upgrade and CRSP's strengthened balance sheet from a convertible note offering.
In a separate development, Natera (NTRA) secured a 30% ongoing royalty in its patent litigation against ArcherDx and Invitae, reinforcing its intellectual property in the molecular residual disease (MRD) testing market. This legal victory for NTRA could impact competitive dynamics within the genomic testing space.
Earlier, ARKG demonstrated conviction in Tempus AI by acquiring an additional $11 million in shares following a price dip, emphasizing a long-term outlook. The fund also participated in broader disruptive technology investments, deploying capital into five undervalued stocks, including a notable stake in
Robinhood Markets (HOOD), though this specific investment was primarily within ARKF and ARKW.
Looking ahead, traders should monitor upcoming earnings reports from key holdings, particularly within the genomic and AI healthcare sectors, as well as any further regulatory developments impacting medical technologies.
